Search Results - "FLEISCHMANN, R" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Global health crises are also information crises: A call to action

Global health crises are also information crises: A call to action

by Xie, Bo, He, Daqing, Mercer, Tim, Wang, Youfa, Wu, Dan, Fleischmann, Kenneth R., Zhang, Yan, Yoder, Linda H., Stephens, Keri K., Mackert, Michael, Lee, Min Kyung
Published in Journal of the American Society for Information Science and Technology (01.12.2020)

Get full text

Journal Article Web Resource

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

by Yazici, Y., McAlindon, T.E., Fleischmann, R., Gibofsky, A., Lane, N.E., Kivitz, A.J., Skrepnik, N., Armas, E., Swearingen, C.J., DiFrancesco, A., Tambiah, J.R.S., Hood, J., Hochberg, M.C.
Published in Osteoarthritis and cartilage (01.10.2017)

Get full text

Journal Article

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

by Mease, P J, Fleischmann, R, Deodhar, A A, Wollenhaupt, J, Khraishi, M, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, van der Heijde, D
Published in Annals of the rheumatic diseases (01.01.2014)

Get full text

Journal Article

Review of head-to-head study designs in rheumatoid arthritis

Review of head-to-head study designs in rheumatoid arthritis

by R, Fleischmann, R, Landewé, J S, Smolen
Published in Seminars in arthritis and rheumatism (01.12.2016)

Get full text

Journal Article

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study

by Gladman, D., Fleischmann, R., Coteur, G., Woltering, F., Mease, P. J.
Published in Arthritis care & research (2010) (01.07.2014)

Get full text

Journal Article

Predicting the impact of scientific concepts using full-text features

Predicting the impact of scientific concepts using full-text features

by McKeown, Kathy, Daume III, Hal, Chaturvedi, Snigdha, Paparrizos, John, Thadani, Kapil, Barrio, Pablo, Biran, Or, Bothe, Suvarna, Collins, Michael, Fleischmann, Kenneth R., Gravano, Luis, Jha, Rahul, King, Ben, McInerney, Kevin, Moon, Taesun, Neelakantan, Arvind, O'Seaghdha, Diarmuid, Radev, Dragomir, Templeton, Clay, Teufel, Simone
Published in Journal of the Association for Information Science and Technology (01.11.2016)

Get full text

Journal Article

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

by Fleischmann, R, Vencovsky, J, van Vollenhoven, R F, Borenstein, D, Box, J, Coteur, G, Goel, N, Brezinschek, H-P, Innes, A, Strand, V
Published in Annals of the rheumatic diseases (01.06.2009)

Get full text

Journal Article

SAT0106 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH 1 OR >1 PRIOR TUMOR NECROSIS FACTOR INHIBITOR FAILURES

SAT0106 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH 1 OR >1 PRIOR TUMOR NECROSIS FACTOR INHIBITOR FAILURES

by Fleischmann, R., Genovese, M. C., Maslova, K., Leher, H., Praestgaard, A., Burmester, G. R.
Published in Annals of the rheumatic diseases (01.06.2020)

Get full text

Journal Article

FRI0122 EFFICACY AND PATIENT-REPORTED OUTCOME MEASURES FROM A TWO-PART MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL TRIAL OF REPOSITORY CORTICOTROPIN INJECTION FOR PERSISTENTLY ACTIVE RHEUMATOID ARTHRITIS

FRI0122 EFFICACY AND PATIENT-REPORTED OUTCOME MEASURES FROM A TWO-PART MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL TRIAL OF REPOSITORY CORTICOTROPIN INJECTION FOR PERSISTENTLY ACTIVE RHEUMATOID ARTHRITIS

by Fleischmann, R., Furst, D., Wan, G., Panaccio, M., Liu, J., Zhu, J., Brasington, R.
Published in Annals of the rheumatic diseases (01.06.2020)

Get full text

Journal Article

FRI0092 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS

FRI0092 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS

by Fleischmann, R., Genovese, M. C., Maslova, K., Leher, H., Praestgaard, A., Burmester, G. R.
Published in Annals of the rheumatic diseases (01.06.2020)

Get full text

Journal Article

POS0086 ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFT

POS0086 ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFT

by Fleischmann, R., Haraoui, B., Buch, M. H., Gold, D., Sawyerr, G., Shi, H., Diehl, A., Lee, K.
Published in Annals of the rheumatic diseases (01.06.2021)

Get full text

Journal Article

Experimental observation of a fundamental length scale of waves in random media

Experimental observation of a fundamental length scale of waves in random media

by Barkhofen, S, Metzger, J J, Fleischmann, R, Kuhl, U, Stöckmann, H-J
Published in Physical review letters (01.11.2013)

Get more information

Journal Article

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

by van der Heijde, D, Fleischmann, R, Wollenhaupt, J, Deodhar, A, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, Mease, P J
Published in Annals of the rheumatic diseases (01.01.2014)

Get full text

Journal Article

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis

by Davis, J C, van der Heijde, D M, Braun, J, Dougados, M, Clegg, D O, Kivitz, A J, Fleischmann, R M, Inman, R D, Ni, L, Lin, S-L, Tsuji, W H
Published in Annals of the rheumatic diseases (01.03.2008)

Get full text

Journal Article

Whole-Genome Comparison of Mycobacterium tuberculosis Clinical and Laboratory Strains

Whole-Genome Comparison of Mycobacterium tuberculosis Clinical and Laboratory Strains

by Fleischmann, R D, Alland, D, Eisen, J A, Carpenter, L, White, O, Peterson, J, DeBoy, R, Dodson, R, Gwinn, M, Haft, D, Hickey, E, Kolonay, J F, Nelson, W C, Umayam, L A, Ermolaeva, M, Salzberg, S L, Delcher, A, Utterback, T, Weidman, J, Khouri, H, Gill, J, Mikula, A, Bishai, W, Jacobs, Jr, W R, Venter, J C, Fraser, C M
Published in Journal of Bacteriology (01.10.2002)

Get full text

Journal Article

POS0653 IMPACT OF UPADACITINIB OR ADALIMUMAB AS INITIAL THERAPY ON THE ACHIEVEMENT OF 48-WEEK TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: POST HOC ANALYSIS OF A PHASE 3 STUDY

POS0653 IMPACT OF UPADACITINIB OR ADALIMUMAB AS INITIAL THERAPY ON THE ACHIEVEMENT OF 48-WEEK TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: POST HOC ANALYSIS OF A PHASE 3 STUDY

by Mysler, E., Tanaka, Y., Kavanaugh, A., Aletaha, D., Taylor, P. C., Song, I. H., Shaw, T., Song, Y., Demasi, R., Ali, M., Fleischmann, R.
Published in Annals of the rheumatic diseases (01.06.2021)

Get full text

Journal Article

POS0087 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY

POS0087 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY

by Fleischmann, R., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Tanaka, Y., Swierkot, J., Khan, N., Bu, X., LI, Y., Song, I. H.
Published in Annals of the rheumatic diseases (01.06.2021)

Get full text

Journal Article

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

by Fautrel, B, Zhu, B, Taylor, P C, van de Laar, M, Emery, P, De Leonardis, F, Kannowski, C L, Nicolay, C, Kadziola, Z, De La Torre, I, Fleischmann, R
Published in Rheumatic & musculoskeletal diseases open (01.04.2020)

Get full text

Journal Article

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

by van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Published in Arthritis care & research (2010) (01.07.2017)

Get full text

Journal Article

FRI0240 Clinical trial to determine whether altering the regimen of pegloticase administration can increase the frequency of subjects having sustained lowering of serum urate

FRI0240 Clinical trial to determine whether altering the regimen of pegloticase administration can increase the frequency of subjects having sustained lowering of serum urate

by Saag, K., Feinman, M., Baraf, H.S., Fleischmann, R., Kavanaugh, A., Lipsky, P.
Published in Annals of the rheumatic diseases (01.06.2018)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[20]